Pasithea Therapeutics Corp.
KTTANasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $486,559 | $15,062 | — |
| Operating income | −$20.9M | −$14.2M | −$16.0M | −$12.6M | −$4.5M | −$40,984 |
| Net income | −$20.4M | −$13.9M | −$16.0M | −$13.9M | −$2.2M | −$40,984 |
| Total assets | $60.2M | $16.1M | $26.1M | $45.2M | $53.3M | $247,958 |
| Total liabilities | $5.0M | $1.3M | $2.7M | $2.7M | $1.9M | $6,603 |
| Equity | $55.2M | $14.8M | $23.4M | $42.5M | $51.4M | $241,355 |
| EPS (diluted) | $-2.91 | $-12.69 | $-0.42 | $-1.76 | $-0.21 | $0.00 |
| Shares out. | 2.7M | 1.0M | 26.1M | 22.9M | 23.0M | 7.5M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −37.0%
- Return on assets
- −33.9%
- Return on capital (ROCE)
- −37.7%
- Liabilities / assets
- 8.3%
- Debt / equity
- 0.09×
- Book value / share
- $20.41
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 11.04safe
- Accruals / assets
- −8.7%clean
- Piotroski F-Score
- 3/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 1 warning● 3 good- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Nov 16, 2021
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1Recruitingreadout ~2026-02PAS-004 in Patients With Advanced Solid Tumors
- Phase 1Recruitingreadout ~2027-09PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Ameriprise Financial IncPassive (13G)May 15, 2026
- Funicular Funds, LpPassive (13G)Apr 22, 2026
- Opaleye Management Inc.Passive (13G)Apr 8, 2026
- Coastlands Capital LpPassive (13G)Feb 27, 2026
- Squadron Capital Management LlcPassive (13G)Feb 17, 2026
- Cvi Investments, Inc.Passive (13G)Feb 17, 2026
- Adage Capital Management, L.P.Passive (13G)Feb 12, 2026
- Janus Henderson Group PlcPassive (13G)Dec 8, 2025
- Vivo Opportunity Fund Holdings, L.P.Passive (13G)Dec 5, 2025
- Armistice Capital, LlcPassive (13G)May 15, 2025
- Intracoastal Capital, LlcPassive (13G)May 12, 2025
- Orca Capital AgPassive (13G)May 9, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 297,457 | 1.0 | +11.4% |
| Apr 30, 2026 | 267,043 | 1.0 | +17.1% |
| Apr 15, 2026 | 227,972 | 1.0 | +86.1% |
| Mar 31, 2026 | 122,487 | 1.0 | -37.0% |
| Mar 13, 2026 | 194,443 | 2.9 | +12.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Director / officer change · Regulation FD disclosureMay 4, 2026
- Delisting / listing-standard noticeFeb 20, 2026
- Director / officer change · Amended charter or bylaws · Shareholder voteJan 28, 2026
- Other material eventDec 15, 2025
- Entered a material agreement · Unregistered equity sale · Regulation FD disclosureDec 2, 2025
- Regulation FD disclosure · Other material eventNov 25, 2025
- Regulation FD disclosure · Other material eventNov 4, 2025
- Director / officer changeOct 27, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 10-QQUARTERLY REPORTMay 15, 2026
- SCHEDULE 13G/AMay 15, 2026
- 4May 5, 2026
- 4May 5, 2026
- 4May 5, 2026
- 4May 5, 2026
- 4May 5, 2026
- 4May 5, 2026
- 4May 5, 2026
- 3May 5, 2026
- 8-KCURRENT REPORTMay 4, 2026
- SCHEDULE 13GApr 22, 2026
- 3OWNERSHIP DOCUMENTApr 17, 2026
- SCHEDULE 13GApr 8, 2026
- 10-KANNUAL REPORTMar 30, 2026
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.